SCHEMBL22282080

SCHEMBL22282080

COCCCN1CCO[C@@H](C)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD1 P21728 1/20 0.44
▸ KDM1A O60341 1/20 0.43
▸ HTR4 Q13639 1/20 0.39
▸ PDK1 Q15118 1/20 0.38
▸ SIGMAR1 Q99720 2/20 0.36
▸ EBP Q15125 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.34
▸ MAPK1 P28482 2/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CHRM2 P08172 1/20 0.34
▸ CHRM1 P11229 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ SCN1A P35498 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ KCNH2 Q12809 1/20 0.34
▸ SCN2A Q99250 1/20 0.34
▸ SCN3A Q9NY46 1/20 0.34
▸ TSHR P16473 2/20 0.34
▸ CYP2D6 P10635 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22281703 1.00 DRD1 (0.44) DRD1KDM1AHTR4PDK1SIGMAR1
SCHEMBL22281704 1.00 DRD1 (0.44) DRD1KDM1AHTR4PDK1SIGMAR1
SCHEMBL12233664 0.89 DRD1 (0.49) DRD1KDM1APDK1ALDH1A1TDP1
SCHEMBL26817753 0.89 DRD1 (0.49) DRD1KDM1APDK1ALDH1A1TDP1
SCHEMBL22282221 0.83 DRD1 (0.42) DRD1KDM1APDK1SIGMAR1EBP
SCHEMBL22281709 0.83 DRD1 (0.42) DRD1KDM1APDK1SIGMAR1EBP
SCHEMBL22281710 0.83 DRD1 (0.42) DRD1KDM1APDK1SIGMAR1EBP
SCHEMBL23868204 0.82 DRD1 (0.41) DRD1KDM1APDK1SIGMAR1EBP
SCHEMBL22281736 0.82 DRD1 (0.41) DRD1KDM1AHTR4PDK1SIGMAR1
SCHEMBL22282252 0.82 DRD1 (0.41) DRD1KDM1APDK1SIGMAR1EBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4272825-A2 MTORC MODULATORS AND USES THEREOF Aeovian Pharmaceuticals, Inc. (US) 2023-11-08 — — EP disclosed
US-20230331737-A1 MTORC1 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. 2023-10-19 — — US disclosed
EP-4223761-A1 QUINAZOLINE COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-08-09 — — EP disclosed
WO-2021195599-A1 MTORC1 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. (US) 2021-09-30 — — WO disclosed
US-11021492-B2 mTORC modulators and uses thereof AEOVIAN PHARMACEUTICALS, INC. (US) 2021-06-01 — — US disclosed
US-20210002300-A1 MTORC MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. 2021-01-07 — — US disclosed
WO-2020154447-A1 MTORC MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. (US) 2020-07-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331737-A1 MTORC1 MODULATORS AND USES THEREOF MTOR, RPTOR, RICTOR DRD1 4357/4885KDM1A 3376/4885HTR4 4297/4885
US-20210002300-A1 MTORC MODULATORS AND USES THEREOF MTOR, RICTOR, RPTOR DRD1 4780/4885KDM1A 3869/4885HTR4 3756/4885
US-11021492-B2 mTORC modulators and uses thereof MTOR, RICTOR, RPTOR DRD1 4780/4885KDM1A 3869/4885HTR4 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback